CN113433325A - 血清vitronectin在AL型淀粉样变的诊断及疾病分期中的应用 - Google Patents
血清vitronectin在AL型淀粉样变的诊断及疾病分期中的应用 Download PDFInfo
- Publication number
- CN113433325A CN113433325A CN202110633442.XA CN202110633442A CN113433325A CN 113433325 A CN113433325 A CN 113433325A CN 202110633442 A CN202110633442 A CN 202110633442A CN 113433325 A CN113433325 A CN 113433325A
- Authority
- CN
- China
- Prior art keywords
- serum
- vitronectin
- diagnosis
- amyloidosis
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002966 serum Anatomy 0.000 title claims abstract description 55
- 108010031318 Vitronectin Proteins 0.000 title claims abstract description 49
- 102100035140 Vitronectin Human genes 0.000 title claims abstract description 49
- 201000010099 disease Diseases 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 26
- 238000003745 diagnosis Methods 0.000 title claims abstract description 17
- 208000023761 AL amyloidosis Diseases 0.000 title claims abstract description 11
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 title claims abstract description 11
- 238000002965 ELISA Methods 0.000 claims abstract description 17
- 238000011160 research Methods 0.000 claims abstract description 10
- 101000803709 Homo sapiens Vitronectin Proteins 0.000 claims abstract description 4
- 238000001514 detection method Methods 0.000 claims abstract description 4
- 238000007619 statistical method Methods 0.000 claims abstract description 4
- 206010002022 amyloidosis Diseases 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 6
- 238000013211 curve analysis Methods 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000003550 marker Substances 0.000 abstract description 4
- 238000011156 evaluation Methods 0.000 abstract description 3
- 238000003759 clinical diagnosis Methods 0.000 abstract description 2
- 230000000405 serological effect Effects 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 4
- 206010021263 IgA nephropathy Diseases 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 4
- 231100000855 membranous nephropathy Toxicity 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000001049 Amyloid Human genes 0.000 description 3
- 108010094108 Amyloid Proteins 0.000 description 3
- 208000005777 Lupus Nephritis Diseases 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 230000003942 amyloidogenic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000008488 Thlaspi arvense Species 0.000 description 1
- 235000008214 Thlaspi arvense Nutrition 0.000 description 1
- 102100029290 Transthyretin Human genes 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了医学诊断学技术领域的血清vitronectin(Vn)在AL型淀粉样变的诊断及疾病分期中的应用,该方法包括以下步骤:第一步:选取研究对象;第二步:收集并分离入选研究对象血浆;第三步:使用酶联免疫吸附法(ELISA)检测血清vitronectin浓度,使用商品化的人vitronectin酶联免疫吸附法(ELISA)检测试剂盒(货号L170419709,Cloud‑Clore Corp)进行检测;第四步:使用SPSS 20.0进行统计分析;第五步:临床应用:血清vitronectin浓度作为临床血清标记物,协助AL型淀粉样变的诊断及严重程度评估,本成果为AL型淀粉样变的临床诊疗提供了新的无创血清学诊断标志物血清vitronectin,可以检测出疾病及预测疾病严重程度,便于对患者进行及时、个体精准化治疗。
Description
技术领域
本发明涉及医学诊断学技术领域,具体为血清vitronectin在AL型淀粉 样变的诊断及疾病分期中的应用。
背景技术
AL型淀粉样变是一种蛋白质异常折叠疾病,异常的浆细胞克隆产生异常 的免疫球蛋白轻链或片段,异常折叠形成淀粉样纤维丝沉积于全身多个组织 和器官。发病率低,AL型淀粉样变性病发病率占0.3/10万人口,但由于缺乏 有效的治疗手段,中位数生存时间仅为20.4个月,5年生存率是19.6%,致 死率很高。由于发病隐匿,许多AL型淀粉样变性病患者起病时已有多器官受 累、处于疾病晚期,从而失去了治疗时机。早期诊断和早期治疗至关重要, 寻找无创性的早期诊断、疾病分期的诊断标志物可让患者临床获益。
我们的前期研究利用显微切割-质谱分析的蛋白组学方法,在AL型淀粉 样变的肾组织中沉积的淀粉样蛋白中检测到了大量的vitronectin(Vn),而 正常瘤旁肾组织对照中未检测到vitronectin,提示vitronectin可能参与淀 粉样变性病的蛋白质异常折叠。早在上世纪80年代Dahlback等人利用免疫 组化方法发现vitronectin沉积于肾脏淀粉样沉积物中,2015年,Casadonte 和Winter利用质谱分析对沉积于组织的淀粉样物质进行分析,发现 vitronectin可沉积于不同类型的淀粉样纤维丝中,包括AApoAI、ALλ、ATTR 型淀粉样变。Shin等人的研究提示vitronectin可异常折叠形成的寡聚物或 者纤维丝结构可作为nidus,加速了淀粉样纤维形成最初阶段的成核作用。以 上研究提示vitronectin广泛沉积于淀粉样沉积物中,vitronectin在淀粉样 纤维丝形成过程中起着重要的作用。
Vitronectin(Vn),又称S蛋白,是一种存在于血液、羊水、尿液和部 分组织的多功能粘附蛋白,血清中的含量为0.1-0.4mg/ml,主要由肝细胞产 生,此外视网膜、脑组织、血管平滑肌细胞、血小板、单核细胞、巨噬细胞 及成纤维细胞均可产生少量的Vn。Vn为含有478个氨基酸的单链多肽,其编 码基因位于17号染色体q11位置,长4.5-5kb,由8个外显子和7个内含子 组成,根据vitronectin的功能特性,将vitronectin分为5个区域。根据 其功能区域,vitronectin生理条件下主要参与细胞粘附、凝血功能、免疫防 御等。
但血清vitronectin如何参与组织淀粉样纤维丝的形成?血清 vitronectin水平是否可对淀粉样变的诊断和严重程度进行预测,既往尚未被 研究。因此,本研究为首次评估血清vitronectin与淀粉样变的相关性极其 诊断价值。
发明内容
本发明的目的在于提供血清vitronectin在AL型淀粉样变的诊断及疾病 分期中的应用,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:血清vitronectin在AL型 淀粉样变的诊断及疾病分期中的应用,该方法包括以下步骤:
第一步:选取研究对象,并签署研究知情同意书;
第二步:收集并分离入选研究对象血浆;
(1)抽取研究对象外周血5ml,放置于惰性分离胶促凝管;
(2)离心1000g×5min;
(3)取上层血清并分装至Eppendorf管;
第三步:使用酶联免疫吸附法(ELISA)检测血清vitronectin浓度,使 用商品化的人vitronectin酶联免疫吸附法(ELISA)检测试剂盒(货号 L170419709,Cloud-CloreCorp)进行检测;
第四步:使用SPSS 20.0进行统计分析;
(1)对比不同疾病组、不同Mayo分期组(使用Mayo分期对疾病严重程 度进行评估)血清vitronectin水平;
(2)使用ROC曲线分析方法选择最佳的血清vitronectin诊断界限值:
第五步:临床应用:血清vitronectin浓度作为临床血清标记物,协助 淀粉样变的诊断及严重程度评估。
与现有技术相比,本发明的有益效果是:本成果为AL型淀粉样变的临床 诊疗提供了新的无创血清学诊断标志物:血清vitronectin,可以检测出疾病 及预测疾病严重程度,便于及时对患者进行及时、个体精准化治疗。
附图说明
图1为本发明AL型淀粉样变和疾病对照组的血清vitronectin(Vn)水 平示意图;
图2为本发明不同Mayo分期组血清vitronectin水平示意图;
图3为本发明ROC分析示意图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行 清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而 不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做 出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
请参阅图1-3,本发明提供一种技术方案:血清vitronectin在AL型淀粉 样变的诊断及疾病分期中的应用,该方法包括以下步骤:
第一步:选取研究对象,并签署研究知情同意书;
第二步:收集并分离入选研究对象血浆;
(1)抽取研究对象外周血5ml,放置于惰性分离胶促凝管;
(2)离心1000g×5min;
(3)取上层血清并分装至Eppendorf管;
第三步:使用酶联免疫吸附法(ELISA)检测血清vitronectin浓度,使 用商品化的人vitronectin酶联免疫吸附法(ELISA)检测试剂盒(货号 L170419709,Cloud-CloreCorp)进行检测;
第四步:使用SPSS 20.0进行统计分析;
(1)对比不同疾病组、不同Mayo分期组(使用Mayo分期对疾病严重程 度进行评估)血清vitronectin水平;
(2)使用ROC曲线分析方法选择最佳的血清vitronectin诊断界限值:
第五步:临床应用:血清vitronectin浓度作为临床血清标记物,协助 淀粉样变的诊断及严重程度评估;
具体的方法:本研究收集了经肾活检确诊的AL型淀粉样变性病患者85 例、疾病对照组117例(膜性肾病31例、IgA肾病32例、狼疮性肾炎29例、 糖尿病肾病25例)的血标本及临床资料并随访,对比AL型淀粉样变不同治 疗方案的有效性及安全性,使用ELISA法检测血清vitronectin浓度;
结果:AL型淀粉样变的平均血清vitronectin水平(65207.8±23846.8ng/ml)显著低于肾炎对照组(IgA肾病72174.2±16549.8ng/ml,狼 疮性肾炎80334.8±29091.8ng/ml,膜性肾病100198.2±39676.9ng/ml,糖 尿病肾病72575.9±9764.7ng/ml,具体见图1),且Mayo分期越严重,血清 vitronectin水平越低(见图2)。AL型淀粉样变中,血清vitronectin水平 与血肌酐水平(r=-0.403,P=0.007)、血浆白蛋白(r=-0.326,P=0.031)、 血红蛋白(r=-369,P=0.014)呈负相关,与eGFR呈正相关(r=-0.323,P=0.035)。 ROC曲线分析提示,血清vitronectin<62398ng/ml可以预测诊断AL型淀粉 样变性病的特异度为79.1%,敏感度为60.0%,曲线下面积为0.74(见图3)。
结论:AL型淀粉样变性患者的血清vitronectin水平显著低于其他肾病 组,且疾病越严重(Mayo分期)、血清vitronectin水平越低。血清vitronectin <62398ng/ml可以预测诊断AL型淀粉样变性病的特异度为79.1%,敏感度为 60.0%。
图1中为AL型淀粉样变(AL)血清Vn为65207.8±23846.88ng/ml,IgA 肾病(IgA)血清Vn为72174.2±16549.8ng/ml,狼疮性肾炎(LN)血清Vn 为80334.8±29091.8ng/ml,膜性肾病(MN)血清Vn为100198.2± 39676.9ng/ml,糖尿病肾病(DN)血清Vn为72575.9±9764.7ng/ml;
图2中为Mayo分期越严重,血清vitronectin水平越低;
图3中为ROC分析:血清Vn<62398ng/ml可以预测诊断AL型淀粉样变 性病的特异度为79.1%,敏感度为60.0%,曲线下面积为0.74。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而 言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行 多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限 定。
Claims (1)
1.血清vitronectin在AL型淀粉样变的诊断及疾病分期中的应用,其特征在于:该方法包括以下步骤:
第一步:选取研究对象,并签署研究知情同意书;
第二步:收集并分离入选研究对象血浆;
(1)抽取研究对象外周血5ml,放置于惰性分离胶促凝管;
(2)离心1000g×5min;
(3)取上层血清并分装至Eppendorf管;
第三步:使用酶联免疫吸附法(ELISA)检测血清vitronectin浓度,使用商品化的人vitronectin酶联免疫吸附法(ELISA)检测试剂盒(货号L170419709,Cloud-Clore Corp)进行检测;
第四步:使用SPSS 20.0进行统计分析;
(1)对比不同疾病组、不同Mayo分期组(使用Mayo分期对疾病严重程度进行评估)血清vitronectin水平;
(2)使用ROC曲线分析方法选择最佳的血清vitronectin诊断界限值;
第五步:临床应用:血清vitronectin浓度作为临床血清标记物,协助AL型淀粉样变的诊断及严重程度评估。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110633442.XA CN113433325A (zh) | 2021-06-07 | 2021-06-07 | 血清vitronectin在AL型淀粉样变的诊断及疾病分期中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110633442.XA CN113433325A (zh) | 2021-06-07 | 2021-06-07 | 血清vitronectin在AL型淀粉样变的诊断及疾病分期中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113433325A true CN113433325A (zh) | 2021-09-24 |
Family
ID=77803979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110633442.XA Pending CN113433325A (zh) | 2021-06-07 | 2021-06-07 | 血清vitronectin在AL型淀粉样变的诊断及疾病分期中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113433325A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113274411A (zh) * | 2021-04-21 | 2021-08-20 | 西安市第一医院 | 经基因修饰的骨髓间充质干细胞来源的微囊泡在制备治疗肾损伤药物中的应用 |
CN115125316A (zh) * | 2022-08-19 | 2022-09-30 | 中国医学科学院北京协和医院 | 肠道菌群在诊断转甲状腺素蛋白淀粉样变性中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2529256A1 (en) * | 2003-06-23 | 2004-12-29 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
US20090047694A1 (en) * | 2007-08-17 | 2009-02-19 | Shuber Anthony P | Clinical Intervention Directed Diagnostic Methods |
US20100323381A1 (en) * | 2008-02-08 | 2010-12-23 | Bergen Iii Harold R | Classifying amyloidosis |
-
2021
- 2021-06-07 CN CN202110633442.XA patent/CN113433325A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2529256A1 (en) * | 2003-06-23 | 2004-12-29 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
US20090047694A1 (en) * | 2007-08-17 | 2009-02-19 | Shuber Anthony P | Clinical Intervention Directed Diagnostic Methods |
US20100323381A1 (en) * | 2008-02-08 | 2010-12-23 | Bergen Iii Harold R | Classifying amyloidosis |
Non-Patent Citations (3)
Title |
---|
MORIE A. GERTZ等: "Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018", 《BLOOD CANCER JOURNAL 》 * |
刘晓霞;武金宝;: "胃肠道淀粉样变性研究进展", 胃肠病学 * |
陈丹,刘志红: "淀粉样变性的分子致病机制及其治疗", 肾脏病与透析肾移植杂志 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113274411A (zh) * | 2021-04-21 | 2021-08-20 | 西安市第一医院 | 经基因修饰的骨髓间充质干细胞来源的微囊泡在制备治疗肾损伤药物中的应用 |
CN115125316A (zh) * | 2022-08-19 | 2022-09-30 | 中国医学科学院北京协和医院 | 肠道菌群在诊断转甲状腺素蛋白淀粉样变性中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nieuwhof et al. | Thin GBM nephropathy: premature glomerular obsolescence is associated with hypertension and late onset renal failure | |
KR101939964B1 (ko) | 급성 신장 손상의 발견 또는 감시 방법, 장치 및 키트 | |
CN113433325A (zh) | 血清vitronectin在AL型淀粉样变的诊断及疾病分期中的应用 | |
JP4447641B2 (ja) | 虫垂炎を診断するための方法およびデバイス | |
WO1997008560A1 (en) | QUANTITATION OF p97 TO DIAGNOSE AND MONITOR ALZHEIMER'S DISEASE | |
US20160377615A1 (en) | Method for evaluation of function of phagocyte | |
JP2013545087A (ja) | 脳損傷のバイオマーカー | |
JPWO2009051259A1 (ja) | 肝疾患診断用バイオマーカー | |
JP2014518624A (ja) | ニューログラニン診断キットのためのアッセイ試薬 | |
KR20200112728A (ko) | 실명 유발 주요 안질환 진단용 혈액 마커 및 이를 이용한 진단 방법 | |
Prabha et al. | Haptoglobin patterns in essential hypertension and associated conditions–increased risk for Hp 2-2 | |
JP3989837B2 (ja) | 抗ラミニン−1抗体の測定法およびその応用 | |
KR102314642B1 (ko) | 파브리 병 진단용 바이오 마커 및 이의 용도 | |
WO2013079721A1 (en) | Marker and method for diagnosing diarrhea syndrome | |
Suen et al. | Analysis of charge distribution of lambda-and kappa-IgA in IgA nephropathy by focused antigen capture immunoassay | |
US20020098188A1 (en) | Blood coagulation factor-activating protein and antibody thereto | |
US20060211038A1 (en) | Methods for detecting vasculopathies and tumors | |
RU2725850C1 (ru) | Способ ранней диагностики хронического тубулоинтерстициального повреждения почек у пациентов с анкилозирующим спондилитом | |
Karakoyun et al. | Serum Fetuin A and Secreted Phosphoprotein 24 as Diagnostic Markers in Inflammatory Bowel Disease | |
JP2015503106A (ja) | テネイシンcおよび関節リウマチにおけるその使用 | |
Hemmingsen et al. | The urinary excretion of ten plasma proteins in long‐term renal transplant patients | |
CN112379106B (zh) | Fmr1蛋白在肾功能不全或肾衰竭诊断中的应用 | |
Kalmárb et al. | PAX2 Mutation-Related Oligomeganephronia in a Young Adult Patient | |
Shentova et al. | Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease | |
JP3776189B2 (ja) | 肥大型心筋症の判定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210924 |